European Commission approves Plegridy for treatment of Relapsing Remitting MS - Biogen Idec

Biogen Idec announced that the European Commission (EC) has on 23 July 2014 granted marketing authorization for Plegridy (peginterferon beta-1a) as a treatment for adults with relapsing-remitting Multiple Sclerosis (RRMS), the most common form of Multiple Sclerosis (MS). Plegridy is dosed once every two weeks and is administered subcutaneously with the Plagridy PEN, a new ready-to-use autoinjector, or a prefilled syringe. Plegridy, the only pegylated interferon approved for use in RRMS, has been proven to significantly reduce important measures of disease activity, including number of relapses, MRI brain lesions, and disability progression.

The EC approval of Plegridy is based on results from one of the largest pivotal studies of a beta interferon conducted, ADVANCE 1, which involved more than 1,500 patients with relapsing forms of MS.